OncoSil Medical Receives TGA Approval in Australia
Filed with ASX · · 3 pages · English
Summary by 6ix AI
OncoSil Medical has received approval from the Australian Therapeutic Goods Administration for its OncoSil device, which treats pancreatic cancer. This marks a significant milestone for the company as it is the first TGA approved Class III medical device targeting pancreatic tumors directly. The approval is expected to enhance market adoption and support future regulatory approvals in other international markets. CEO Nigel Lange emphasized the importance of this achievement for Australian patients and the company's global commercialization strategy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from OncoSil Medical
- Security Class Reinstatement to Quotation - OSLOE
- Security Class Suspension from Quotation
- Appendix 4D and Half Year Accounts
- CEO Remuneration Update
- Capital Raising Presentation
Later from OncoSil Medical
- OncoSil progresses HDE with US FDA
- OncoSil Selected for Major European Pancreatic Cancer Study
- OncoSil Medical Files for FDA Approval
- OncoSil Medical Completes Manufacturing Validation
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical